Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street

Journal of Immunology

Volumn 195, Issue 3, 2015, Pages 755-761

  Barrett, David M ^a   Grupp, Stephan A ^a,b   June, Carl H ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; CD19 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; ARTICLE; BIOCHEMICAL COMPOSITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CELL EXPANSION; COLITIS; CYTOKINE RELEASE SYNDROME; DISEASE MODEL; HUMAN; HYPOPHYSITIS; LYMPHOCYTE DIFFERENTIATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RASH; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VITILIGO; ADVERSE EFFECTS; ANIMAL; BIOLOGICAL THERAPY; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; LEUKEMIA, B-CELL; LYMPHOMA; MOUSE; PROCEDURES;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD19; CELL ENGINEERING; CELL- AND TISSUE-BASED THERAPY; GENETIC ENGINEERING; HUMANS; LEUKEMIA, B-CELL; LYMPHOMA; MICE; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84937707232     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500751     Document Type: Article

References (88)

1. June, C. H., S. R. Riddell, and T. N. Schumacher. 2015. Adoptive cellular therapy: a race to the finish line. Sci. Transl. Med. 7: 280ps7.
2. Riddell, S. R., M. Elliott, D. A. Lewinsohn, M. J. Gilbert, L. Wilson, S. A. Manley, S. D. Lupton, R.W. Overell, T. C. Reynolds, L. Corey, and P. D. Greenberg. 1996. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 2: 216-223.
3. Scholler, J., T. Brady, G. Binder-Scholl, W.-T. Hwang, G. Plesa, K. Hege, A. Vogel, M. Kalos, J. Riley, S. Deeks, et al. 2012. Decade-long safety and function of retroviralmodified chimeric antigen receptor T cells. Sci. Transl. Med. 4: 132ra153.
4. Ho, Y. C., L. Shan, N. N. Hosmane, J. Wang, S. B. Laskey, D. I. Rosenbloom, J. Lai, J. N. Blankson, J. D. Siliciano, and R. F. Siliciano. 2013. Replicationcompetent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155: 540-551.
5. Hütter, G., D. Nowak, M. Mossner, S. Ganepola, A. Müssig, K. Allers, T. Schneider, J. Hofmann, C. Kücherer, O. Blau, et al. 2009. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360: 692-698.
6. Rossi, J. J., C. H. June, and D. B. Kohn. 2007. Genetic therapies against HIV. Nat. Biotechnol. 25: 1444-1454.
7. Deng, K., M. Pertea, A. Rongvaux, L. Wang, C. M. Durand, G. Ghiaur, J. Lai, H. L. McHugh, H. Hao, H. Zhang, et al. 2015. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517: 381-385.
8. Taylor, P. A., C. J. Lees, and B. R. Blazar. 2002. The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99: 3493-3499.
9. Tang, Q., K. J. Henriksen, M. Bi, E. B. Finger, G. Szot, J. Ye, E. L. Masteller, H. McDevitt, M. Bonyhadi, and J. A. Bluestone. 2004. In vitro-expanded antigenspecific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199: 1455-1465.
10. Brunstein, C. G., J. S. Miller, Q. Cao, D. H. McKenna, K. L. Hippen, J. Curtsinger, T. Defor, B. L. Levine, C. H. June, P. Rubinstein, et al. 2011. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117: 1061-1070.
11. Hippen, K. L., S. C. Merkel, D. K. Schirm, C. M. Sieben, D. Sumstad, D. M. Kadidlo, D. H. McKenna, J. S. Bromberg, B. L. Levine, J. L. Riley, et al. 2011. Massive ex vivo expansion of human natural regulatory T cells (Tregs) with minimal loss of in vivo functional activity. Sci. Transl. Med. 3: 83ra41.
12. Hippen, K. L., S. C. Merkel, D. K. Schirm, C. Nelson, N. C. Tennis, J. L. Riley, C. H. June, J. S. Miller, J. E. Wagner, and B. R. Blazar. 2011. Generation and largescale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am. J. Transplant. 11: 1148-1157.
13. Zanin-Zhorov, A., Y. Ding, S. Kumari, M. Attur, K. L. Hippen, M. Brown, B. R. Blazar, S. B. Abramson, J. J. Lafaille, and M. L. Dustin. 2010. Protein kinase C-u mediates negative feedback on regulatory T cell function. Science 328: 372-376.
14. Mekala, D. J., and T. L. Geiger. 2005. Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes. Blood 105: 2090-2092.
15. Moisini, I., P. Nguyen, L. Fugger, and T. L. Geiger. 2008. Redirecting therapeutic T cells against myelin-specific T lymphocytes using a humanized myelin basic protein-HLA-DR2-z chimeric receptor. J. Immunol. 180: 3601-3611.
16. Riley, J. L., C. H. June, and B. R. Blazar. 2009. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 30: 656-665.
17. Esensten, J. H., D. Wofsy, and J. A. Bluestone. 2009. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 5: 560-565.
18. Jethwa, H., A. A. Adami, and J. Maher. 2014. Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time? Clin. Immunol. 150: 51-63.
19. Hwu, P., J. C. Yang, R. Cowherd, J. Treisman, G. E. Shafer, Z. Eshhar, and S. A. Rosenberg. 1995. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55: 3369-3373.
20. Barrett, D. M., N. Singh, X. Liu, S. Jiang, C. H. June, S. A. Grupp, and Y. Zhao. 2014. Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy 16: 619-630.
21. Barrett, D. M., N. Singh, D. L. Porter, S. A. Grupp, and C. H. June. 2014. Chimeric antigen receptor therapy for cancer. Annu. Rev. Med. 65: 333-347.
22. Brentjens, R. J., E. Santos, Y. Nikhamin, R. Yeh, M. Matsushita, K. La Perle, A. Quintás-Cardama, S. M. Larson, and M. Sadelain. 2007. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13: 5426-5435.
23. Lee, J. C., E. Hayman, H. J. Pegram, E. Santos, G. Heller, M. Sadelain, and R. Brentjens. 2011. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 71: 2871-2881.
24. Mardiros, A., C. Dos Santos, T. McDonald, C. E. Brown, X. Wang, L. E. Budde, L. Hoffman, B. Aguilar, W. C. Chang, W. Bretzlaff, et al. 2013. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 122: 3138-3148.
25. Milone, M. C., J. D. Fish, C. Carpenito, R. G. Carroll, G. K. Binder, D. Teachey, M. Samanta, M. Lakhal, B. Gloss, G. Danet-Desnoyers, et al. 2009. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17: 1453-1464.
26. Grupp, S. A., M. Kalos, D. Barrett, R. Aplenc, D. L. Porter, S. R. Rheingold, D. T. Teachey, A. Chew, B. Hauck, J. F. Wright, et al. 2013. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368: 1509-1518.
27. Maude, S., N. Frey, P. Shaw, R. Aplenc, D. Barrett, N. Bunin, A. Chew, V. Gonzalez, Z. Zheng, S. Lacey, et al. 2014. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371: 1507-1517.
28. Davila, M. L., C. C. Kloss, G. Gunset, and M. Sadelain. 2013. CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS ONE 8: e61338.
29. Kochenderfer, J. N., Z. Yu, D. Frasheri, N. P. Restifo, and S. A. Rosenberg. 2010. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116: 3875-3886.
30. Pegram, H. J., J. C. Lee, E. G. Hayman, G. H. Imperato, T. F. Tedder, M. Sadelain, and R. J. Brentjens. 2012. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119: 4133-4141.
31. Rongvaux, A., T. Willinger, J. Martinek, T. Strowig, S. V. Gearty, L. L. Teichmann, Y. Saito, F. Marches, S. Halene, A. K. Palucka, et al. 2014. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 32: 364-372.
32. van der Stegen, S. J., D. M. Davies, S. Wilkie, J. Foster, J. K. Sosabowski, J. Burnet, L. M. Whilding, R. M. Petrovic, S. Ghaem-Maghami, S. Mather, et al. 2013. Preclinical in vivo modeling of cytokine release syndrome induced by ErbBretargeted human T cells: identifying a window of therapeutic opportunity? J. Immunol. 191: 4589-4598.
33. Irving, B. A., and A. Weiss. 1991. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-Associated signal transduction pathways. Cell 64: 891-901.
34. Romeo, C., and B. Seed. 1991. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64: 1037-1046.
35. Letourneur, F., and R. D. Klausner. 1991. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc. Natl. Acad. Sci. USA 88: 8905-8909.
36. Kuwana, Y., Y. Asakura, N. Utsunomiya, M. Nakanishi, Y. Arata, S. Itoh, F. Nagase, and Y. Kurosawa. 1987. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem. Biophys. Res. Commun. 149: 960-968.
37. Roberts, M. R. 1997. Chimeric receptor molecules for delivery of co-stimulatory signals. United States patent application 08/455,860. Publication No. US5686281 A. 1997 Nov 11.
38. Finney, H. M., and A. D. G. Lawson. 2003. Chimeric cytoplasmic signalling molecules derived from CD137. United States patent application 10/399,364. Publication No. US20040038886 A1. 2002 Apr 25.
39. Carpenito, C., M. C. Milone, R. Hassan, J. C. Simonet, M. Lakhal, M. M. Suhoski, A. Varela-Rohena, K. M. Haines, D. F. Heitjan, S. M. Albelda, et al. 2009. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA 106: 3360-3365.
40. Davila, M. L., I. Riviere, X. Wang, S. Bartido, J. Park, K. Curran, S. S. Chung, J. Stefanski, O. Borquez-Ojeda, M. Olszewska, et al. 2014. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6: 224ra25.
41. Long, A. H., W. M. Haso, J. F. Shern, K. M. Wanhainen, M. Murgai, M. Ingaramo, J. P. Smith, A. J. Walker, M. E. Kohler, V. R. Venkateshwara, et al. 2015. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21: 581-590.
42. Frigault, M. J., J. Lee, M. C. Basil, C. Carpenito, S. Motohashi, J. Scholler, O. U. Kawalekar, S. Guedan, S. E. McGettigan, A. D. Posey, Jr., et al. 2015. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 3: 356-367.
43. Porter, D. L., B. L. Levine, M. Kalos, A. Bagg, and C. H. June. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365: 725-733.
44. Kochenderfer, J. N., W. H. Wilson, J. E. Janik, M. E. Dudley, M. Stetler-Stevenson, S. A. Feldman, I. Maric, M. Raffeld, D. A. Nathan, B. J. Lanier, et al. 2010. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116: 4099-4102.
45. Maude, S. L., D. Barrett, D. T. Teachey, and S. A. Grupp. 2014. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 20: 119-122.
46. Lee, D. W., R. Gardner, D. L. Porter, C. U. Louis, N. Ahmed, M. Jensen, S. A. Grupp, and C. L. Mackall. 2014. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124: 188-195.
47. Teachey, D. T., S. R. Rheingold, S. L. Maude, G. Zugmaier, D. M. Barrett, A. E. Seif, K. E. Nichols, E. K. Suppa, M. Kalos, R. A. Berg, et al. 2013. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121: 5154-5157.
48. Kalos, M., B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg, and C. H. June. 2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3: 95ra73.
49. Morgan, R. A., J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot, and S. A. Rosenberg. 2010. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18: 843-851.
50. Linette, G. P., E. A. Stadtmauer, M. V. Maus, A. P. Rapoport, B. L. Levine, L. Emery, L. Litzky, A. Bagg, B. M. Carreno, P. J. Cimino, et al. 2013. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122: 863-871.
51. Cameron, B. J., A. B. Gerry, J. Dukes, J. V. Harper, V. Kannan, F. C. Bianchi, F. Grand, J. E. Brewer, M. Gupta, G. Plesa, et al. 2013. Identification of a Titinderived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5: 197ra103.
52. Morgan, R. A., N. Chinnasamy, D. Abate-Daga, A. Gros, P. F. Robbins, Z. Zheng, M. E. Dudley, S. A. Feldman, J. C. Yang, R. M. Sherry, et al. 2013. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36: 133-151.
53. Lee, D. W., J. N. Kochenderfer, M. Stetler-Stevenson, Y. K. Cui, C. Delbrook, S. A. Feldman, T. J. Fry, R. Orentas, M. Sabatino, N. N. Shah, et al. 2015. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385: 517-528.
54. Rapoport, A. P., E. A. Stadtmauer, N. Aqui, D. Vogl, A. Chew, H. B. Fang, S. Janofsky, K. Yager, E. Veloso, Z. Zheng, et al. 2009. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin. Cancer Res. 15: 4499-4507.
55. Grupp, S. A., E. L. Prak, J. Boyer, K. R. McDonald, S. Shusterman, E. Thompson, C. Callahan, A. F. Jawad, B. L. Levine, C. H. June, and K. E. Sullivan. 2012. Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Clin. Cancer Res. 18: 6732-6741.
56. Marin, V., E. Cribioli, B. Philip, S. Tettamanti, I. Pizzitola, A. Biondi, E. Biagi, and M. Pule. 2012. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum. Gene. Ther. Methods 23: 376-386.
57. Mestas, J., and C. C. Hughes. 2004. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172: 2731-2738.
58. Straetemans, T., M. Coccoris, C. Berrevoets, E. Treffers-Westerlaken, C. E. Scholten, D. Schipper, T. L. Ten Hagen, and R. Debets. 2012. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies. Hum. Gene Ther. 23: 187-201.
59. Abe, R., P. Vandenberghe, N. Craighead, D. S. Smoot, K. P. Lee, and C. H. June. 1995. Distinct signal transduction in mouse CD4+ and CD8+ splenic T cells after CD28 receptor ligation. J. Immunol. 154: 985-997.
60. Maus, M. V., B. Kovacs, W. W. Kwok, G. T. Nepom, K. Schlienger, J. L. Riley, D. Allman, T. H. Finkel, and C. H. June. 2004. Extensive replicative capacity of human central memory T cells. J. Immunol. 172: 6675-6683.
61. Berger, C., M. C. Jensen, P. M. Lansdorp, M. Gough, C. Elliott, and S. R. Riddell. 2008. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118: 294-305.
62. Kalos, M., and C. H. June. 2013. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39: 49-60.
63. Thomas, A. K., M. V. Maus, W. S. Shalaby, C. H. June, and J. L. Riley. 2002. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin. Immunol. 105: 259-272.
64. Kaneko, S., S. Mastaglio, A. Bondanza, M. Ponzoni, F. Sanvito, L. Aldrighetti, M. Radrizzani, S. La Seta-Catamancio, E. Provasi, A. Mondino, et al. 2009. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 113: 1006-1015.
65. Maus, M. V., A. K. Thomas, D. G. Leonard, D. Allman, K. Addya, K. Schlienger, J. L. Riley, and C. H. June. 2002. Ex vivo expansion of polyclonal and antigenspecific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol. 20: 143-148.
66. Paulos, C. M., C. Carpenito, G. Plesa, M. M. Suhoski, A. Varela-Rohena, T. N. Golovina, R. G. Carroll, J. L. Riley, and C. H. June. 2010. The inducible costimulator (ICOS) is critical for the development of human TH17 cells. Sci. Transl. Med. 2: 55ra78.
67. Gattinoni, L., E. Lugli, Y. Ji, Z. Pos, C. M. Paulos, M. F. Quigley, J. R. Almeida, E. Gostick, Z. Yu, C. Carpenito, et al. 2011. A human memory T cell subset with stem cell-like properties. Nat. Med. 17: 1290-1297.
68. Graef, P., V. R. Buchholz, C. Stemberger, M. Flossdorf, L. Henkel, M. Schiemann, I. Drexler, T. Höfer, S. R. Riddell, and D. H. Busch. 2014. Serial transfer of singlecell-derived immunocompetence reveals stemness of CD8+ central memory T cells. Immunity 41: 116-126.
69. Gattinoni, L., X. S. Zhong, D. C. Palmer, Y. Ji, C. S. Hinrichs, Z. Yu, C. Wrzesinski, A. Boni, L. Cassard, L. M. Garvin, et al. 2009. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 15: 808-813.
70. Moon, E., C. Carpenito, J. Sun, L. Wang, V. Kapoor, J. Predina, D. Powell, Jr., J. Riley, C. H. June, and S. M. Albelda. 2011. 2011. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17: 4719-4730.
71. Abastado, J.-P. 2012. The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Cancer Res. 72: 2159-2161.
72. Awwad, M., and R. J. North. 1990. Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors. Cancer Res. 50: 2228-2233.
73. Ganss, R., E. Ryschich, E. Klar, B. Arnold, and G. J. Hämmerling. 2002. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62: 1462-1470.
74. Pinthus, J. H., T. Waks, V. Malina, K. Kaufman-Francis, A. Harmelin, I. Aizenberg, H. Kanety, J. Ramon, and Z. Eshhar. 2004. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J. Clin. Invest. 114: 1774-1781.
75. Ward-Kavanagh, L. K., J. Zhu, T. K. Cooper, and T. D. Schell. 2014. Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer. Cancer Immunol Res 2: 777-788.
76. Qiao, J., T. Kottke, C. Willmon, F. Galivo, P. Wongthida, R. M. Diaz, J. Thompson, P. Ryno, G. N. Barber, J. Chester, et al. 2008. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat. Med. 14: 37-44.
77. Duval, L., H. Schmidt, K. Kaltoft, K. Fode, J. J. Jensen, S. M. Sorensen, M. I. Nishimura, and H. von der Maase. 2006. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin. Cancer Res. 12: 1229-1236.
78. Cieri,N., B. Camisa, F. Cocchiarella, M. Forcato,G. Oliveira, E. Provasi, A. Bondanza, C. Bordignon, J. Peccatori, F. Ciceri, et al. 2013. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121: 573-584.
79. Guedan, S., X. Chen, A. Madar, C. Carpenito, S. E. McGettigan, M. J. Frigault, J. Lee, A. D. Posey, Jr., J. Scholler, N. Scholler, et al. 2014. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood 124: 1070-1080.
80. Hinrichs, C. S., A. Kaiser, C. M. Paulos, L. Cassard, L. Sanchez-Perez, B. Heemskerk, C. Wrzesinski, Z. A. Borman, P. Muranski, and N. P. Restifo. 2009. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114: 596-599.
81. Lamers, C. H., S. Sleijfer, A. G. Vulto, W. H. Kruit, M. Kliffen, R. Debets, J. W. Gratama, G. Stoter, and E. Oosterwijk. 2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24: e20-e22.
82. Zhao, Y., E. Moon, C. Carpenito, C. M. Paulos, X. Liu, A. L. Brennan, A. Chew, R. G. Carroll, J. Scholler, B. L. Levine, et al. 2010. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70: 9053-9061.
83. Beatty, G. L., A. R. Haas, M. V. Maus, D. A. Torigian, M. C. Soulen, G. Plesa, A. Chew, Y. Zhao, B. L. Levine, S. M. Albelda, et al. 2014. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2: 112-120.
84. Di Stasi, A., S. K. Tey, G. Dotti, Y. Fujita, A. Kennedy-Nasser, C. Martinez, K. Straathof, E. Liu, A. G. Durett, B. Grilley, et al. 2011. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365: 1673-1683.
85. Wiek, C., E. M. Schmidt, K. Roellecke, M. Freund, M. Nakano, E. J. Kelly, W. Kaisers, V. Yarov-Yarovoy, C. M. Kramm, A. E. Rettie, and H. Hanenberg. 2015. Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol. Biochem. J. 465: 103-114.
86. Tebas, P., D. Stein, W. W. Tang, I. Frank, S. Q. Wang, G. Lee, S. K. Spratt, R. T. Surosky, M. A. Giedlin, G. Nichol, et al. 2014. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370: 901-910.
87. Torikai, H., A. Reik, F. Soldner, E. H. Warren, C. Yuen, Y. Zhou, D. L. Crossland,H.Huls,N. Littman, Z. Zhang, et al. 2013. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122: 1341-1349.
88. Prosser, M. E., C. E. Brown, A. F. Shami, S. J. Forman, and M. C. Jensen. 2012. Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol. Immunol. 51: 263-272.